Loading company
Cognition Therapeutics Inc.
CGTX · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$0.95+1.7%Sep 29 close
- 1M
- -6.7%
- 6M
- +60.1%
- 1Y
- -29.5%
CGTX · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$0.95+1.7%Sep 29 close
Cognition Therapeutics Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$3.9M | -$6.7M | +41.61% |
| Profit per share | -$0.04 | -$0.11 | +63.64% |
| Free Cash Flow | -$8.4M | -$3.7M | -125.71% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cognition Therapeutics Inc. has no earnings call transcript available.
“The second quarter marked important progress across both our clinical and corporate priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cognition Therapeutics Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.